variable_name,section_header,ui,label,value_constraints,field_note,units,CDE Reference,source_file,source_directory,Digest (variable_name|source_file|source_directory)
limit_of_blank,Analytical Performance,float,"Limit of Blank (LOB).  The highest apparent analyte concentration expected to be found when a replicate of a sample containing no analyte are tested. Concentration units must be specified in the ""Units"" column! For qualitative tests.",,"Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S49-52. PMID: 18852857; PMCID: PMC2556583.",,https://ncbi.nlm.nih.gov/pmc/articles/PMC2556583,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,405dd426978d9fb64f1b6208853661ad0f199b34b18e8bce81a90f4a1b7f960e560306ac67ab780a8d6e651a69a857bb805f8c06c90922534586df1d987dfb6d
limit_of_detection,Analytical Performance,float,"Limit of Detection (LOD). The minimum amount or concentration of analyte that can be reliably distinguished from zero. Concentration units must be specified in the ""Units"" column! For qualitative tests.",,"Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S49-52. PMID: 18852857; PMCID: PMC2556583.",,https://ncbi.nlm.nih.gov/pmc/articles/PMC2556583,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,69bf619afa77cbb07468e562db888624e85a80ca3f2fd2c6968062415080d30b9713d68734682c0c148ca19d04566aef2e8938c9a73b44d68d451e586f968caa
limit_of_detection_sn_ratio,Analytical Performance,float,Signal to noise ratio used to define the limit of detection in standard deviations.,,Example: 3,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,4fca8870c58396cbf68da887a39f900932e6e2784d5fcc3ed1b83b51c005f42f65f053ffa3a7306a217936ff9ae8b253b86507b9ba9402a852a2fb443c5a1326
limit_of_detection_detail,Analytical Performance,text,Description of how limit of detection was determined.,,"Example: A dilution series of heat inactivated SARS-CoV-2 virus stock (USA-WA1/2020) was prepared in natural clinical matrix (pooled nasopharyngeal swab samples eluted in VTM). Five (5) replicates were tested per dilution. The testing was performed as per the recommended instructions for use, with the virus in clinical matrix applied directly onto the Swab until the saturation of the flocked tip. The estimated LoD concentration for verification was selected as the concentration in between the dilution factor that returned 5/5 positive test outcomes (100%) and the next dilution factor that returned 0/5 positive (0%) based on the qualitative result. Source: https://www.fda.gov/media/144592/download.",,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,e8262299229c6a86301e0ff60e67d25ebe70548b12dbe12fc3bd304eca3d2c167d403b2f3edf1eb52375bd5550679226da598826dbeeb9a29bd9b3e8c9b6311b
limit_of_quantitation,Analytical Performance,float,"Limit of Quantiation (LOQ). The minimum amount or concentration of analyte in the test sample that can be quantified with acceptable precision. Concentration units must be specified in the ""Units"" column! For quantiative tests.",,"Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S49-52. PMID: 18852857; PMCID: PMC2556583.",,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,09a18df2d729c02dbb8971a8e0e8b5f1864184f3742106eb76fbd52c4bcc3dbc5a23bb24cb9a91f7d86714ed8fed3a1e87608bed98179a8bba1904c4a56ef6ad
limit_of_quantitation_sn_ratio,Analytical Performance,float,Signal to noise ratio used to define the limit of quantification in standard deviations.,,Example: 5,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,d6ce86a104ecdeacea3e069803e67889718bb5cf6dfb7c0031a9d0827ad83a82b24ae222a47960c3e83c896fc250dd6cad15316e4225339998eedfaf120c1b80
limit_of_quantitation_detail,Analytical Performance,text,Description of how limit of quantition was determined.,,"
COVID-19 Home Test was tested with up to a concentration
of 106.43 TCID 50 /mL of heat inactivated SARS-CoV-2 virus
(USA-WA1/2020 Isolate). Source: https://www.fda.gov/media/144592/download.",,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,090c0bb365ac4a2cb552e42d4d8528536dbcbd24896d8c5457519ee125d2891267ab06ee7ef52450f1206eb66cdb3ebab623aab5f687d01380be926c49ab80a6
dynamic_range_min,Analytical Performance,float,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,d8f0da6abd075acc88970ae0cfc0904a6284088dcacec78f220e8213e8374f9c5f3b28947af89cb042f89193cdb824f457a0a15bdaa4faf689538f1e086c3f93
dynamic_range_max,Analytical Performance,float,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,e196e21be0f31677de02b5b6a950d3729af84a61cf46eb3632d5ae4bfd27ea43a71b42c859ca7c19dbcee21fee5bc5e8d0e058876d07870618ab129ddaf94ac2
high_dose_hook_effect,Analytical Performance,text,Description of high dose hook effect.,,Example: No high dose hook effect was observed when the Ellume COVID-19 Home Test was tested with up to a concentration of 106.43 TCID 50 /mL of heat inactivated SARS-CoV-2 virus (USA-WA1/2020 Isolate). Source: https://www.fda.gov/media/144592/download.,,https://www.olink.com/faq/what-is-the-high-dose-hook-effect/,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,2f125c18f15e44e8dea8c8377996db2b1d817c36f73c1171023428c0852ca479bdbf37ccea5913deded9378263b6fac2d0dd16db540c5b15d7093931c50d9d74
non_clinical_sensitivity,Analytical Performance,float,The proportion of system-based positives; calculated as 100xTP/(TP+FN). Used for comparison with a VQA standard.,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,64b5e13a610a5947d6df15914c5a9d4d08a0a9e342171322d24d5b9083d4fd16863de67de00a3987453420d047a1ca730c8338156aba73eb21af7e2335ede6a7
non_clinical_selectivity,Analytical Performance,float,The proportion of system-based negatives; calculated as 100xTN/(TN+FP). Used for comparison with a VQA standard.,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,d9dd8c5ca0b907e968ac26b517d98d104b15eb2ab04ec66893685c880b285d6913320db92542f4d035474ba0aeeae212a42fd889644d5d9074379fd3ee3f6c23
area_under_the_roc_curve,Analytical/Clinical Performance,float,ROC-based performance. AUC under ROC curve.,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,c193cb5b59a6977b1e28a6f840796ecf99de1faf711795e67dd3ef94d3970050e6be2c9d837144090f64c1a3798c3ff98d9541d537c9f1194dbc0c9e426dd876
roc_x_values,Analytical/Clinical Performance,list,List of false positive rate values (1-specificity),,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,3b0b1e727951ccbe61a5f1ff789ccd97f272a38d403f958232b722edbb986b1f541ff636590c796dc85424924b5730df542a68344ad116f89991913ad665a00e
roc_y_values,Analytical/Clinical Performance,list,List of true positive rate values (sensitivity),,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,35431a3d446c48141c535b3f1be8dddb63ff9000e123cbb8480c8e6826f9ef74249fe554a0c95740b60187808e1afb61d77c0eb0a4113c4f48de539d65d9cc22
analytical_sensitivity,Analytical Performance,float,Analytical sensitivity is defined as the slope of the calibration curve.,,"Armbruster DA, Pry T. Limit of blank, limit of detection and limit of quantitation. Clin Biochem Rev. 2008 Aug;29 Suppl 1(Suppl 1):S49-52. PMID: 18852857; PMCID: PMC2556583; https://www.youtube.com/watch?v=8Pe3k3fJNe8",,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,04bb6729db6da0140b1145453ef8eec5b2c4bf0c1fd56ddd278ee0b220ba91346846633b4b43c39421d1de2b1e142fc775b54aaf9932c909f41bed4bc93ebd63
analytical_sensitivity_unit,Analytical Performance,text,Unit of analytical sensitivity,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,9e80e20f28f800bb28549238c6d5a51850b23a5dd4191b8fc697b8e57fcdd33cdc05833fe70c9fef6fba6fadb36554675154720f25feed6b0364dd09396169a5
analytical_inclusivity,Analytical Performance,text,Impact of variants/mutations on test results. Specificity with respect to variants/mutations compared to wildtype,,Analysis can be in silico and wet testing,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,0d0078b98763c633c65769e8ef9d10ea58c7762c86dd5da54b3ffaceade4a5f53d6d1e9310871f8f327d89025128814d5369627bc598f80d3130f0ac82571a92
cross_reactivity_organism,Analytical Performance,text,Name of organism tested for cross-reactivity against target organism,,Example: Human coronavirus OC43,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,588c7f02ccfbce4bf17320cb105e4635c33e186726cadfe33d7039029684069f237bdce6a9ccddc05408e2183911617acd851bce53a0178af299e4f0ecefbd12
cross_reactivity_organism_concentation,Analytical Performance,float,Concentration of cross-reacting organism.,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,d79fa84381f7347b4a6ac9cea72499505b6df972b0fea5ea94ee079b4776f419e1bd363caec5ef691b46766ebaddf44a0c91c1bf7364f1ac68d7f6b6166c57af
cross_reactivity_organism_concentation_unit,Analytical Performance,text,Concentation unit used for cross-reacting organism.,,Example: copies/ml,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,3a5eda5cd090ecdc4e06d923e0311d9c925fb96beb34fe332927f0e4b93caadc64c9ef12deeb87b80f648263e4ad10cd48c3ae27618a52703c71cfa2242cf152
cross_reactivity_result,Analytical Performance,category,Result of cross-reactivity test against target organism. A positive results indicates that cross-reacting organism gives a positive signal.,positive | negative | inconclusive,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,7ea3671bcc82dd3995e8f1391f8db903912729c7b0dc23966ff10098d1bbb27a20513342d026a64be8c484e0528970616bc650d923f3c1e4f8c6093b873bcb6c
cross_reactivity_detail,Analytical Performance,text,Description of observed cross-reactivity.,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,d884ed9c3eb51e6684787ca1aeff3f3761e4d439409ce5e8b06fe59cd6acb1e2f60b1b4ebfb5cd9ceb7aea95f03e23911b43b64e4bc55c354bf4f156c19f2e50
interfering_substance,Analytical Performance,text,Name of the interfering substance.,,Example: Menthol,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,09549895c49920839c2d0222194461ba321480860c55daa88e2dc34b896228c3ef7176b170757bbf93df34a5a0cb8ce168d1d89900def839baf8b69a1716b875
interfering_substance_provider,Analytical Performance,text,Name of the entity that provided the interfering substance.,,Example: Sigma Aldrich,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,ccf6b876a418380757da9f48ce64cc935420fd1cd590ab101ca88cfb14d9910e8790663e1f3e655be05cb807c4be1520427479f7f3f95bad89e98ce78458763c
interfering_substance_concentration,Analytical Performance,list,Concentration of the interfering substance.,,Example: 1.5,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,caabb88af6330f147e2f965d99a48327c4955fe9d4a3a5682487ad390c388d16c26a723812dfb362c8834c94d328b4264ca1b2a2838350bdb1df812b641bd6ef
interfering_substance_concentation_unit,Analytical Performance,text,Concentration unit  used for interfering substance.,,"Examples: mg/ml, %v/v",,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,5d86ed0cf8eafff36804aa6a068ec3fbc23548b959c8fe5b6af082c7e6a251e46c012ef1bc5d1c193d73ef1a553310ec3d5b1eaf975b7aaa39c7127933ea770e
interfering_substance_detail,Analytical Performance,text,Description of observed interference.,,"Example:  There was no interference of SARS-CoV-2 detection
observed from any of the substances tested except for
bleach which was shown to interfere at the initial
concentration of 1% v/v tested. Further testing indicated that
the highest bleach level the test system could tolerate was
0.2% v/v. Source: https://www.fda.gov/media/144592/download.",,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,1a17878eafc0876c1edb9387387c52e404833b7a02480a46b4d102620806878dde2989d11d181e846cff5640a19ec7a721e60108ca461eb2292169f62512db87
positive_percent_agreement,Analytical/Clinical Performance,float,Positive Percent Agreement (PPA). The proportion of non-reference standard positive subjects in whom the new test is positive.,,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,6de846d792179e1611f1d7e8e79e201afe68f74dc2e9b4a19d2a20c3cc7d75f5e50a045ece65df6f23f9daad6823bf0e6022313b9747fbda8f76fd37de90fe7b
negative_percent_agreement,Analytical/Clinical Performance,float,Negative Percent Agreement (NPA). The proportion of non-reference standard negative subjects in whom the new test is negative.,,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,dfbd45ae12901f3338de1cd49e548ecc110564ab53a17e0d2fd04e3e5a7570f959b7d06f008e80f635c0da25d0c9503dd9e3996dc21d275b24fbe3fd6239eecd
overall_percent_agreement,Analytical/Clinical Performance,float,"Percentage of total subjects where the
new test and the non-reference standard agree.",,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,cb6d84ab3ea0826ef23b57444b9d5513a04f0db4396193b7cb5d710a7b7a1323c45b5741dcb5d03fda2402616cb2800fd8a074c07cc3ef8ec223ad8850e707a1
target_condition,Clinical Performance,text,"A particular disease, a disease stage, health status, or any other identifiable condition within a patient, such as staging a disease already known to be present, or a health condition that should prompt clinical action, such as the initiation, modification, or termination of treatment.",,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,e599010a3d921439581780afdb4802231636643635c05481030eced2c6fc29f3f9289b91a744105f6ccaad41954ecc2516d0a50af4ace5b69b7dfb3e14453218
reference_standard,Clinical Performance,text,"The best available method for establishing the presence or absence of the target condition; the reference standard can be a single test or method, or a combination of methods and techniques, including clinical follow-up.",,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,196500fd7eb1d27b564e067c398a0b92069b9bd930491e805030547e66eca912c8bb582af86db79f20a980ba08dbddf0754c1ffb4e07d7d38582d69105a9d40c
study_population,Clinical Performance,text,The subjects/patients (and specimen types) included in the study,,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,c6d251d296f92f3d912cf10146f32a6369ff3dc8aaefd92012255306737b53ca4ad27488737c7d8106348b0e5a59146446fe46afd1f3014c93e7e6fb9c9c2555
stratification,Clinical Performance,text,"Stratification of subjects, e.g., days since onset of symptoms, asymptomatic vs. symptomatic, co-infections, PCR Cycle Threshold, n x LOD concentration ranges for contrived samples, number of subjects in each category in a separate data elements.",,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,58449e1fbf6bdc4315a445b08949a8a89131326e57eeca08d5f499ac86e86655a276a1d998b76af1747dcbcfe1ab9d00758a07ec667401549e88b9abe86d17c9
true_positives,Clinical Performance,integer,True Positives (TP). The number of subjects/specimens with true positive test results,,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,09f8b6c76fd9cd212ac581271af25e617ec1347b5027779da195dc0fe03d5b2d8e17a2eda421b1d4fda325a5a3868c62799ea8b699bd8d3da5921d9e689b68ab
false_positives,Clinical Performance,integer,False Positives (FP). The number of subjects/specimens with false positive test results,,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,20804184902a74a391bfaafd1b11d2606e9ac01b684471ad4b2cc3d44fb144a873c037d5c10710b90acf58925f125d8ac3121fe7062334bdd4e1d8bf55973bba
true_negatives,Clinical Performance,integer,True Negatives (TN). The number of subjects/specimens with true negative test results.,,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,e9ca4dd3bdec7af2a93220d9a81143e4ecc98209674a9b488fe9f44f5d276ac5b8772c1716230b562fe1dad196e94a2782a3557a757e74576073ddf6432bb6d9
false_negatives,Clinical Performance,integer,False Negatives (FN). The number of subjects/specimens with false negative test results,,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,53a74706ea6a00ff1ea64d67d428914a6a22bf1128535145f8284a8b358c868e99459faf4cc804a910463a2093099c9cedf86e5616f67d9cdf41b27d956d2e6e
clinical_sensitivity,Clinical Performance,float,The proportion of subjects with the target condition in whom the test is positive; calculated as 100xTP/(TP+FN). Used for comparison with a reference (Gold) standard.,,PCR is Gold standard for COVID-19. For comparison with a non-reference standard use percent agreement metrics.,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,5e0413e68ac249ef580a24ef47dff1f3950c27650b0f9d71fe76f093e67a966cec6e75f1c7cc23c73e614feb4201497e89bdd0d5641502d8f63724927bb62133
clinical_sensitiviy_ci_percent,Clinical Performance,float,Percent used to define two-sided confidence interval.,,Example: 95,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,8e6d5710ea231b7f861ee81a0c72bc1bb76ad4cb91f00de48f2f72c8e6c4009ff17bb916cac40d98de7939935a21ab435d5f6d1b6aa950ebda58d1075a0e2a85
clinical_sensitivity_ci_min,Clinical Performance,float,Lower bound of confidence interval.,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,4776bdd447ed28212c89795d4d65786699b9aded08fff8fdc687969d32e681a6294af48419d9b799bd98ea0ffdfc9a0369581337ca68df0baaff6d596ad72c2e
clinical_sensitvity_ci_max,Clinical Performance,float,Upper bound of confidence interval.,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,0df82bddec4209f5a3fdfe51c8e0c7cd1238f76b80b2723220a7dacbf2b6632b2f5c3a036a071d1c8cd3e3fa4e05a9c37bdbd9ebdef318a0b7e79cd123313c52
clinical_specificity,Clinical Performance,float,The proportion of subjects without the target condition in whom the test is negative; calculated as 100xTN/(FP+TN).,,PCR is Gold standard for COVID-19. For comparison with a non-reference standard use percent agreement metrics.,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,02464e031f227a55e167438e2208b12da144c62d003cdbe14ce4e08c69d124ef041b3269ee98ce5c1bdc2b9ab02a0198dc6817f039fc0696b3b3e0fa6f26ef31
positive_predictive_value,Clinical Performance,float,The proportion of test positive patients who have the target condition; calculated as 100xTP/(TP+FP),,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,7a499fb5f45d766ae8afc40ddc979cc5b4f935282a33fe8e49b8fa3c10ae4a0280fb0c75886b51915bb572c818aeb37c178d52757524b18f5036e72f692cc52f
negative_predictive_value,Clinical Performance,float,The proportion of test negative patients who do not have the target condition; calculated as 100xTN/(TN+FN),,,,https://www.fda.gov/files/medical%20devices/published/Guidance-for-Industry-and-FDA-Staff---Statistical-Guidance-on-Reporting-Results-from-Studies-Evaluating-Diagnostic-Tests-%28PDF-Version%29.pdf,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,cef0102ca17914f9772341d2d99148a3b780ba08f626c0abdf81b0a489b90647e4c1c8fcbdf52f2048f74021e26e7cd7b82b2e7e98beffcdd3ad90e0bcce82fb
clinical_cutoff,Clinical Performance,float,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,d75bc279205473cd449449fd124508e1d554ab010a0e84b782e62a6a7b22542b06dfda9db50da83a20e4f62bdd3d8f8332281ab4cdb59fb3398b9d51e4c981fa
invalid_test_rate,Clinical Performance,float,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,123f0090f4a59161c3d90fa357bded4425833a65780228f34c05cc98f115be411cfa5a59f79f87939eee287ad63ca74021b6aecaed49dfb1ac2ef2432a46ca14
invalid_test_detail,Clinical Performance,text,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,5cf05d595f578d158e5f4ffb21fe61597bb614a937763e5c4d6a1481f741cef7ca2c712873d0be5e51e1ce9e21d6302a7ab0d5c0c6d3d4a40171a97cfa28516c
turnaround_time,Clinical Performance,integer,TAT,,,minutes,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,8eebe247afe316c2830bd5e3e0fda132a339c9c127476f0942e2735f1a015a7eca44e6604e8a1d7d6c5b72f6e2f090074b123dfe99910efccac63ca894bc1db6
price_per_test,Clinical Performance,float,,,,usd,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,d900002f28590f57cbaec84f410f72a2dc07f5eb06bdd74cf3c58e80916c5de923524a559c0e948e1921d7ef72c0e3fc715a3805eb7d2c645695a9de0bb9a307
calibration curve,Clinical Performance,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,9bc4b2611780b18af8b3d485fbce0a0b1b292d73eb9943453ad9a03cd8b261a126af6e98a85cf3da1f8bd9dac34b0918918263e978863a0cba49ef9bced6a8c6
quality control samples,Clinical Performance,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,0c12fc5042d4fac5c4f6e746fdcc6d0faa202026fc2c5c8a14b9b1d67b3d00946bc228d5b95d7260ca8b374bde3d6edf726ff5d93c3e0270375a2239f701c816
selectivity and specificity,You have clinical_ sensitivity and specificity - do you need a separate one for analytical selectivity and specificity?,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,0f18ec9e284f270ae1c20fc96ff74e134dd54e9f5930c88135b145373a34eaf5439af536b8662bd1ba46c27c6043f73ae7b63a7165947eb29bcecfcf3c1f74e8
sample size impact,This came up yesterday in Gail's meeting too,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,31f76aa4ce234e15986b3832e0c77299c0c978e4519be33d8392129de98b59a9ba7e321f4c7160476233ca14c1cd3663d3598698df9e58951a71a688637bbbc6
"accuracy, precision, and recovery",Accuracy is accounted for through specificity and sensitivity - how about precision?,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,6ad70e270c0ae3dd075f0f41a92ed185e9c916e1c34aaf324a932e31076097392b52c13560c6176c70c8f344c0476b4652fca3ec374fda7d8c8edf0ad3678fcf
stability,This came up yesterday in Gail's meeting too,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,6e4ea18fe92ea00240f56c2c739a0fc739019c074e5f8149c99374e4370420caa85118fa8e68432898143b7589054ab48f71172a27b76a133fa20813e66b686b
dilution effects,This came up yesterday in Gail's meeting too,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,8ca6f38f09c40462585a8b38528d1a1fafcd28bd07666e625639f70fec98faf94a1d69db42b27329f43720d87b349bc886493db33ca671669918dd099ffefbb2
partial and cross validations,Cross is covered how about partial?,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,0cd83278d0741c8be5721ac273784b57de9629be081008ae65d2a70b65c3ba42d0350bebcc892d8ccad485934f08060cd4bbac27fd15ce8dec9e5757408557e2
linearity,This could be important when you have multiple maxima and minima,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,2a9f16661cdcc33072a55fa90359da1be500d8f65391a5ed0970d25c24cad8f496dc9e0e61aebd5280c4229e77edf2b8b31fd1898c8d89e862a2335d9caaee5b
"repeatability,",This is important,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,83b53ec4cb66c91a442e507cd010ed9c4a239cf9acca9f3b1729dbd322ae153350e0a85ef5794c6b38cbde1027d6397f1de526d8869abe3845dd769a89add6a3
intermediate precision,This is important,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,783f6bfc3cf16981973173a4059ba5e59e2db9ade5398cac78e05688f15389f80c807b8e30c9673f9541eb6791191b598e4ea3a7a17c21b15fd20df8b92437ce
reproducibility,This is more important,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,30200980a8b4d2f9d6dd34d16734ea3c5ba9638c9a1dfd9ed08aa7bd2a42165537a122160804b502fb76010b7ff56f410f169221e09277398c2c680475e73f1d
range,This is more important,,,,,,,Performance_Metrics_Data_Element_Template_v000.xlsx [RADxrad_Data_Element_Template_v].csv,RADx-rad,abe0cfbcd58766473c4e16c5f87ccdbdb872a1589502f1b902937f9f0d32cf50a1c34174d53ae22fc194e75ba425d63de373680a4a6ac8c1ef9805280adf4bef
